KWF: open calls

Health~Holland PPP call for production technology of medical isotope lead-212 and enabling clinical technologies, run jointly by KWF, NRG PALLAS, FAST and Oncode Institute; requires PPP consortium with private party and Consortium Agreement, Dutch summary reviewed by Patient Advisory Committee.

Add-on funding for ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KIC early detection projects) to define pathways toward clinical/commercial implementation. Requires TTO commitment letter; innovation must have reached at least TRL 3; not for fundamental research or CE-marking costs.

For early-career oncology researchers within 5 years of PhD (extensions possible for clinical training or parental leave) who must lead an independent research line and be employed ≥0.5 FTE/year on the project. Covers basic, credentialing, preclinical, clinical, and implementation research phases; Dutch summary required for Patient Advisory Committee review.

Development Call funds translation of research findings into practice for Creation of Modality, Preclinical, Clinical or Implementation research phases; application types include Research Project, Unique High-Risk and Consortia. Multicenter GI cancer trials with ≥4 centers require a support letter from the relevant national research group at full-proposal stage.

Programme for phase III studies and implementation of validated clinical-grade biomarkers (TRL7-9) into routine Dutch oncology care. Requires a multidisciplinary consortium with min. 4 parties, a project manager, HTA specialist, patient perspective embedded, and a KWF-approved steering committee.

Funds clinical validation (TRL5/6) of already-known cancer biomarkers via multidisciplinary consortia including biostatistician and HTA-expert; mandatory HTA component, patient involvement, and development plan for implementation. AI-component projects must involve the AI4Health consortium as partner or advisor.

Funds basic research and credentialing-phase research into biological and psychosocial mechanisms of cancer, including target/biomarker discovery and observational/cohort studies. Two-stage process: pre-proposal then full proposal by invitation; participating institutes must register in KWF-GMS at least 6 weeks before closing.

Funds academic-led clinical trials (Phase I–III) for new investigational medicinal products (chemical, biological, ATMP) addressing unmet cancer needs. Lead institute must be a medical centre or research institute in the Netherlands. Proposals must be in English. Repurposing of registered drugs and purely preclinical research are out of scope. Patient involvement in trial setup is mandatory.

Co-funding for oncology drug candidates in late-stage preclinical development through to early clinical trials (Phase I/IIa), delivered via KWF's partnership with the Cancer Research UK Centre for Drug Development. Open to Dutch academic groups and (spin-off) companies only; non-Dutch initiators are excluded, and applicants must hold or secure full IP rights and freedom to operate.